Cerity Partners’s Climb Bio CLYM Stock Holding History

Cerity Partners’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,821	Closed	-$37.3K	–	2364
2023 Q4	$37.3K	Buy	+13,821	New	+$36K	﹤0.01%	1823

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Cerity Partners's CLYM Position: Q1 2024 in Review

Cerity Partners sold out of Climb Bio (CLYM) in Q1 2024, closing a stake of 13,821 shares — an estimated $37.3K sold.

Cerity Partners first reported a position in CLYM in Q4 2023 and held it in 1 quarter. The position peaked at $37.3K in Q4 2023. 21 funds tracked by Wall St. Rank hold CLYM as of Q1 2024.

Cerity Partners reported no remaining Climb Bio position as of Q1 2024 after selling out during the quarter.
Cerity Partners sold 13,821 Climb Bio shares in Q1 2024, an estimated $37.3K.
Cerity Partners first reported a position in Climb Bio in Q4 2023 and held it in 1 quarter.
Cerity Partners's Climb Bio position peaked at $37.3K in Q4 2023.
21 funds tracked by Wall St. Rank held Climb Bio as of Q1 2024.

Based on Cerity Partners's 13F filing for Q1 2024, filed 14 May 2024.